Fig. 2: Plasma p181 levels increase at a higher rate over time in A+SCD and A+MCI compared to A+CU, while plasma NfL levels rise at a similar rate in A+CU, A+SCD, and A+MCI. | Molecular Psychiatry

Fig. 2: Plasma p181 levels increase at a higher rate over time in A+SCD and A+MCI compared to A+CU, while plasma NfL levels rise at a similar rate in A+CU, A+SCD, and A+MCI.

From: Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s disease

Fig. 2

Plasma p181 and NfL were measured in plasma samples collected at ~1 year intervals from A+D A + CU and A-CU, B+E A + SCD and A-SCD, and C+F A + MCI and A-MCI. A+B Plasma p181 levels in A + SCD, compared to each A + CU and A-SCD increase more steeply over time. C The rate of change is then kept in MCI. D–F Changes of plasma NfL levels over time are similar in A + CU, A + SCD, and A + MCI, which leads to elevated NfL in A + SCD and A + MCI compared to A + CU individuals. Estimated trajectories for CU (blue), SCD (red), and MCI (green) are drawn using mixed-effects modelling with an interaction term for time and amyloid-positivity, and adjusted for age at baseline, and sex. Shaded areas indicate 95% confidence intervals.

Back to article page